LOS ANGELES — Patients with intracranial aneurysm who respond poorly to the antiplatelet drug clopidogrel when treated with flow diversion using the Pipeline embolization device (Medtronic) have ...
Among patients with acute coronary syndromes undergoing a procedure such as angioplasty, those who received platelet function tests before receiving antithrombotic therapy to determine appropriate ...
The RECLOSE 2–ACS (Responsiveness to Clopidogrel and Stent Thrombosis 2–ACS) trial from Italy provides new information about platelet reactivity but doesn't answer any of the key questions about the ...
When skin is cut or damaged, tiny cell fragments circulating in the blood, called platelets, arrive at the injury and spread out to stop the blood from leaking out. Once enough layers of platelets ...
The document follows two earlier consensus documents, released in 2013 and 2016. Dominick Angiolillo, MD, PhD (University of Florida College of Medicine – Jacksonville), senior author of the paper, ...
Please provide your email address to receive an email when new articles are posted on . Clopidogrel is often the antiplatelet agent of choice for patients with ACS or those receiving a stent because, ...
June 6, 2012 (Munich, Germany) — A new substudy of the ISAR-REACT-4 trial has found that those patients with high on-clopidogrel-treatment platelet reactivity (HPR) randomized to bivalirudin (Angiomax ...
Although switching from clopidogrel to the more potent antiplatelet agent prasugrel generally eliminates high on-treatment platelet reactivity in stable patients following percutaneous coronary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results